Real-world Experience with Favipiravir for Treatment of COVID-19 among Indian Healthcare Professionals.

Tiwaskar, Mangesh; Dhar, Raja; Talwar, Deepak; Ansari, Abdul; Lakhe, Mahesh; Panchal, Sagar; Bhagat, Sagar; Patil, Saiprasad; Barkate, Hanmant

Tiwaskar, Mangesh; Dhar, Raja; Talwar, Deepak; Ansari, Abdul; Lakhe, Mahesh; Panchal, Sagar; Bhagat, Sagar; Patil, Saiprasad; Barkate, Hanmant.

Afiliación

Tiwaskar M; Consultant Physician & Diabetologist, Shilpa Medical Research Centre, Mumbai, Maharashtra.
Dhar R; Director, Pulmonary Medicine, Fortis Hospital, Kolkata, West Bengal.
Talwar D; Director, Metro Centre for Respiratory Diseases, Noida, Uttar Pradesh.
Ansari A; Director, Critical Care, Nanavati Hospital, Mumbai, Maharashtra.
Lakhe M; Consultant ID Specialist, Columbia Asia Hospital, Pune, Maharashtra.
Panchal S; Manager Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra; Corresponding Author.
Bhagat S; Senior Manager,Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra.
Patil S; Team Lead,Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra.
Barkate H; Senior Vice President, Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra.

J Assoc Physicians India ; 69(12): 11-12, 2022 Dec.

Article en En | MEDLINE | ID: mdl-35057588

Asunto(s)

COVID-19; Amidas; Estudios Transversales; Atención a la Salud; Humanos; Pirazinas; SARS-CoV-2

Buscar en Google

Imprimir

XML

PubMed Links

Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Guideline / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Límite: Humans Idioma: En Revista: J Assoc Physicians India Año: 2022 Tipo del documento: Article

Buscar en Google

Imprimir

XML

PubMed Links